Romosozumab Completed Phase 1 Trials for Osteoporosis / Postmenopausal Osteoporosis (PMO) Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT01588509Transition From Alendronate to Romosozumab (AMG 785)
NCT01833754Study of Romosozumab (AMG 785) Administered to Healthy Participants and Patients With Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemodialysis